Introduction
Non-Hodgkin lymphomas (NHL) comprise a heterogeneous group of malignancies, that are classified based on immunophenotyping, morphological and clinical characteristics (1) .
During the last decades, NHL show a steadily increasing incidence. Currently, approximately 4% of cancers in industrial states are non-Hodgkin lymphomas (NHL), with 55.000 new patients every year solely in the United States (US) (2) . During the last years genetic and epigenetic alterations were defined that underlie lymphoma development. These allowed for a better understanding of lymphoid tumor formation. The members of the AP-1 (Activator Protein 1) transcription factor family figure prominently among the molecules that have been implicated in lymphoid transformation (3) (4) (5) (6) .
The transcription factor AP -1 converts extracellular signals into transcriptional changes of specific target genes, and functions in cell proliferation, differentiation, apoptosis and cellular transformation. AP-1 consists of dimers between members of the Fos (c-Fos, FosB, Fra -1, Fra-2), Jun (c-Jun, JunB, JunD) and ATF families of proteins. Extensive analyses of mice and of cell lines have indicated that each family member has distinct biological functions. These are elicited via the cell-type specific regulation of particular subsets of target genes (reviewed in 7, 8, 9) . Components of the AP -1 transcription factor are involved in tumorigenesis by regulating oncogenic transformation, apoptosis and angiogenesis. c-Jun, in particular, has been shown to cooperate with oncogenic ras in cellular transformation (10, 11) and to block the pro-apoptotic activity of p53 during the development of liver tumors in mice (12) .
Moreover, alterations of AP-1 family members have been linked to malignant transformation in several types of human cancer (13) (14) (15) .
C-Jun and JunB proteins are similar in their primary structure and their DNA binding specificity, but differ in their transcriptional capacity. In contrast to c-Jun, a transcriptional activator, JunB acts both as a transcriptional activator and repressor, depending on the promoter context and on the heterodimerization partner (16, 17) . In certain tissues, JunB antagonizes the function of c-Jun (18, 19) and has been shown to negatively regulate tumor formation (20) . The molecular function of JunB has been studied both in vivo and in vitro.
JunB deficient embryos die during embryonic development from vascular defects (21) . In contrast, constitutive overexpression of JunB from the human ubiquitin C (Ubi-junB) promoter has no major consequences in vivo in transgenic mice (22) . In transgenic fibroblasts, JunB directly activates the cyclin dependent kinase inhibitor p16 and inhibits cyclin D1 activity, resulting in reduced pRB phosphorylation and delayed progression from G 1 to S only.
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Most recently, JunB was identified as an important factor in hematopoietic transformation (24, 25) . In fact, mice lacking JunB in the myeloid lineage develop a myeloproliferative disease resembling human chronic myeloid leukemia (CML) (24) . The increased levels of GM-CSF receptor, Bcl 2 and Bcl xl and a decreased expression of p16 within JunB deficient myeloid progenitors most likely account for the expansion of the myeloid compartment (24) .
These findings suggest a role for JunB as a tumor suppressor. In line with this concept, human CML cells display reduced JunB levels due to increased DNA methylation of its promoter, with a further decrease of JunB levels occurring in blast crisis (25) . However, JunB can act as promote tumor growth, by cooperating with c-Jun in the development of murine fibrosarcoma (26). Finally, JunB is overexpressed in human Hodgkin lymphoma but it is apparently transcriptionally inactive (27) . Thus, given the dual function of JunB and its cell-type specific action, it is difficult to predict the role of JunB in transformation of lymphoid cells. In this study we have investigated the expression pattern of JunB in non-Hodgkin lymphomas and addressed the functional role of JunB within the B-lymphoid compartment. 
Materials and Methods

Patient samples and protein analysis
Samples of lymph nodes of patients with lymphoid malignancies were obtained from the Institute of Pathology, University Hospital Graz. The lymphomas were classified according to the REAL classification (1).
Cells were lysed in a buffer containing protease and phosphatase inhibitors (50 mM Hepes, pH 7.5, 0.1% Tween-20, 150 mM NaCl, 1 mM EDTA, 20 mM -glycero-phosphate, 0.1 mM sodium vanadate, 1 mM sodium fluoride, 10 µg/ml each aprotinin and leupeptin and 1mM PMSF). Protein concentrations were determined using a BCA-kit as recommended by the manufacturer (Pierce, Rockford, IL) (28).
100µg total protein/sample was electrophoretically resolved on polyacrylamide gels containing SDS, and transferred onto Immobilon membranes. Membranes were probed with the antibodies indicated in the figure legend. The antisera directed against abl, p16, p21, p27
were obtained from Santa Cruz, the antibody against JunB was a generous gift from M.Yaniv, the c-Jun and Bcl x antibodies were obtained from Transduction Laboratories. Sites of antibody binding were detected using protein A-conjugated horseradish peroxidase (EY Laboratories, San Mateo, CA) with chemiluminescent detection (ECL detection kit, Amersham, Arlington Heights, IL).
Histology and immunohistochemistry
Paraffin-and acrylate-embedded specimens were obtained from the Institute of Pathology, University Hospital Graz. Tissue array technology was employed to compare samples using antibodies against Ki-67, CD20, CD23, CD30, CD-4 (Dako, Glostrup, Denmark) and JunB, c-Jun, c-Fos, Fra-1, JunD (Santa Cruz Biotech, Santa Cruz, USA) and the alkaline phosphatase anti-alkaline phosphatase technique (29) . Samples were rated positive for the individual AP-1 members, when the staining intensity of the tumor cells was consistently higher than the surrounding untransformed cells. In addition, normal lymphnodes were used as controls and stained negative for the AP-1 members investigated under our technical conditions. A further negative control consisted of the staining of tissue sections with the secondary antibody alone.
The livers and spleens of the diseased mice were transferred into 4% PBS buffered formalin for histological examinations. Serial sections were performed and stained with H&E. Three individual spleens and livers from each genotype were analyzed by light microscopy for the infiltration of leukemic cells. The majority of portal fields were investigated. 
Mice and genotypes
Ubi-junB transgenic mice were generated as described (22) and were maintained in a mixed 129/svxC57Bl/6xMF1xHimOF1 genetic background.
Tissue culture conditions and virus preparation
Transformed fetal liver cells and cell lines derived from tumor tissue were maintained in RPMI medium containing 5% heat inactivated fetal calf serum (FCS), 100 U/ml penicillinstreptomycin and 5 µM -mercaptoethanol. NIH3T3 cells, T220-29 cells (NIH3T3 cell engineered to produce interleukin-7) and A010 cells were maintained in DMEM containing 10% heat inactivated FCS and 100 U/ml penicillin-streptomycin. A010 cells produce an ecotropic replication deficient form of the Abelson virus. For collection of the viral supernatant, A010 cells were plated in 100 mm dishes pre-coated with gelatine (1%) and grown to confluence. Supernatant was harvested every 8 hours for 40 hours, pooled and filtered through a 0.45 µm filter (30) . For UV irradiation the cells were exposed to 0,006Joule/cm 2 in RPMI medium. 90 min thereafter the cells were harvested and lysed for western blot analysis.
B and T cell purification, [ 3 H ]Thymidine Incorporation
Splenic B and T cells were MACS sorted for the expression of CD19 and CD3 respectively according to the manufacturers instruction (Miltenyi Biotech). The purity of the cells after MACS was controlled by FACS and was between 85 and 95% in the individual experiments.
For thymidine incorporation assays, the cells were then plated at a density of 2x10 5 Mock infected cells did not result in growth factor independent colonies. The ability to form cell lines was tested by transferring an aliquot of the transduced cells (1x10 6 ) to growth factor free medium. The medium was changed twice a week and the culture observed for the outgrowth of stable clones (31) .
Injection of tumor cells into nude mice
Ten days after infection, 1x10 6 cells were resuspended into 300µl of phosphate buffered saline (PBS) and injected subcutaneous into nude (nu/nu) mice. At the time point of injection the cells had been in growth factor free medium for at least a week and consisted of CD19 + / CD43 + pro B cells. Mice were checked daily for the development of tumors. Tumors bigger than 2 cm in diameter were excised for further analysis (31) .
Infection of neonatal mice with Ab-MuLV
Newborn mice were injected retroperitoneally with 50µl of replication incompetent ecotropic retrovirus encoding for v-abl. The mice were then checked daily for onset of diseases. Sick mice were sacrificed and analysed carefully for signs of disease (30) .
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Results
Low expression of JunB in human B lymphoid malignancies
We Again, a strong expression of JunB was detected in ALCL, whereas a normal or reduced expression of JunB was found by Western blot analysis in B cell lymphomas (figure 1C).
Overexpression of JunB blocks proliferation in murine B, but not T lymphoid cells
In order to investigate the mechanism accounting for the differences in the expression of JunB in B and T cell malignancies, we used a transgenic mouse model that allows us to study the impact of JunB in both lymphoid compartments in vivo. As can be seen in Figure 2A , UbijunB transgenic animals showed an increased expression of JunB in B and T lymphoid cells.
The numbers of B lymphoid cells in the peripheral blood of junB-transgenic animals were found to be reduced to 60% when compared to age-matched wild type littermate controls, whereas the numbers of peripheral T-lymphoid cells were in the same range (data not shown). 
Stimulation of T-cells with increasing concentrations of the lectin Concanavalin
JunB overexpression is accompanied by an increased expression of the cyclin dependent kinase inhibitor protein p16 in B cells
In fibroblasts maintained in culture, overexpression of JunB resulted in upregulation of the cell cycle kinase inhibitor p16, which was proposed to mediate the growth inhibitory effect of JunB (20) . However, it is not known, whether this effect is also seen in vivo, and if it occurs in all cell types. Hence, we selected four tissues reported expressing p16 in wild type adult mice 
JunB overexpression inhibits transformation by the B cell specific v-abl oncogene
To test whether JunB might also be able to counteract transformation in the B-cell lineage, we used the Abelson oncogene (Ab-MulV) (34, 35) . Primary fetal liver cells were infected with a replication-incompetent ecotropic Abelson retrovirus. After 3 days, which allows for expression of the Abelson oncogene the cells were suspended in growth factor free methyl cellulose and the numbers of Pro B cell progenitors were determined in parallel by FACS analysis. As can be seen in figure 5A , the v-abl transduced JunB transgenic fetal liver preparations gave rise to lower numbers of growth-factor independent colonies. Some of the Nevertheless, the basic phenotypical hallmarks of the disease did not differ between JunB transgenic and wild-type animals: all tumors were of B lymphoid origin (CD19/CD43 double positive), the white blood cell counts were elevated in the same range ( figure 5C ) and liver and spleen were the organs most affected by infiltration with tumor cells. Histological sections of spleen and liver revealed that the parenchyma of the spleen and the portal fields in wild type animals were heavily infiltrated by leukemic cells. In the wild type liver leukemic cells were spilling out past the limiting plates of the portal tracts. In contrast, in JunB transgenic animals, spleen and liver were affected to a lesser degree such that the regular organ architecture was maintained ( figure 5D ). We therefore conclude that overexpression of JunB mitigated the severity of v-abl induced disease. This resulted in a prolonged median survival time of JunB transgenic animals.
Abelson transformed pro B cells have escaped the growth inhibition by JunB
In order to understand why protection by JunB was only incomplete, we explanted tumors and propagated the cells in vitro. It was evident that the tumor cells obtained from JunB transgenic animals had overcome the inhibitory effect of the transgene, for we failed to detect any differences between the wild type and JunB transgenic tumor cells in response to mitogenic stimulus (figure 6A). Western blot showed a considerable variation between cell lines derived from JunB transgenic tumors. Regardless of this variability, the levels were consistently higher than in tumor cells from wild type animals ( Figure 6B, top) . The discrepancy between only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From high levels of JunB and normal proliferative capacity suggested that, during transformation and expansion in vivo, the tumor cells had overcome the inhibitory effect of the junB-transgene. In order to verify this conjecture, we determined the levels of p16, an established downstream target of JunB (20) . In 2 out of 4 transgenic tumor cells, the levels of p16 were dramatically reduced. This was also the case for 6 of 10 wild type tumors (figure 6B).
Western blot analysis of the cell cycle regulators D2, E and A and the cell cycle inhibitor protein p21 did not show any major change (data not shown).
V-abl transformed B cells escape growth inhibition by JunB
We therefore speculated that the transformation process might render the cells insensitive to the growth suppressing effect of JunB by inactivating the JunB-dependent pathway that is Immature common lymphoid precursors may also be resistant to growth inhibition by JunB.
In fact we suspect that high levels of JunB may have a growth promoting effect in early lymphoid progenitors, because the numbers of (CD19+/CD43+) B-cell precursors are elevated in the bone marrow of junB-transgenic mice. In contrast, we found that the levels of (CD19+/CD43-) B -cells were reduced by 40% in peripheral blood. Taken together, these observations are indicative of a partial block starting at the level of the pro B-cell stage.
Finally, it is worth mentioning that the variation in AP1-members was also readily evident in human lymphoid malignancies. Tissue array staining showed that cells from BCLL samples were negative for JunB, but highly positive for Fra1 (28 out of 28 samples). By comparison, anaplastic large cell lymphoma (ALCL), a T-cell derived malignancy was characterized by the highest levels of JunB. Thus, 15 out of 17 samples were strongly positive by tissue array staining. These were also highly positive for c-Jun. Our data are consistent with a recent report that shows high AP1-activity in three cell lines derived from ALCL (27) . Further experiments need to determine whether this effect is specific for v-abl or whether elevated JunB levels are capable to interfere with transformation induced by other oncogenes.
According to the high expression levels of JunB in ALCL and the lack of p16 induction by mitogenic stimulation in T cells we expect the tumor suppressing action of JunB to be limited to the B lymphoid lineage.
To the best of our knowledge, there is no comparable systematic survey of AP1-members in a large set of non-Hodgkin lymphoma by tissue array. However, JunB expression was assessed in a limited number of human cutaneous lymphomas by DNA microarray. JunB expression was lost in 3 out of 4 primary cutaneous B cell lymphomas (39) , whereas JunB was amplified in primary cutaneous T cell lymphomas (40) . Similarly, the level of JunB has been determi- (27) . The vast majority of Hodgkin lymphomas are thought to originate from B cells although the pathogenesis has remained elusive (41, 42) . It has been noted that Hodgkin-lymphomas express c-Jun and JunB at high levels (27) . Regardless of the different status of Hodgkin and non-Hodgkin lymphoma, it is worth pointing out that these cells also escape from growth inhibition by JunB. In spite of the very high levels of JunB that presumably arise from constitutive activation of NF-B, JunB is transcriptionally inactive in Hodgkin lymphoma (27) . These observations again support our conclusion, namely that high levels of transcriptionally active JunB are incompatible with B-lymphoid transformation.
We have not systematically investigated all possible mechanisms that may underlie the escape. However, in several cell lines derived from explanted murine tumors, we observed a loss of p16 expression, which is a target gene for JunB (20) . This loss is per se sufficient to Given the various escape mechanisms that are likely to be operative at the time point of diagnosis, it is at present, however, difficult to predict the prognostic role of JunB. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 7 days, the bulk cultures, which now consisted of 80% CD19+/CD43 cells were subjected to [ 3 H]-thymidine incorporation assay after stimulation with 10ng/ml IL-7 (B). 
